Abstract: Medullary thyroid carcinoma is a malignant tumor derived from neuroendocrine cells,which can be hereditary or sporadic.Its molecular genetic alterations mainly include RET gene mutation and RAS gene mutation.Surgery is the main treatment modality for early medullary thyroid carcinoma.Targeted therapy is an important therapeutic alternative for recurrent or advanced medullary thyroid carcinoma.Targeted therapeutic agents currently available for relapsed or advanced medullary thyroid carcinoma include Vandetanib,Carbozantinib,Anlotinib,Pralsetinib and Selpercatinib.The molecular genetics alterations of medullary thyroid carcinoma and progress in targeted therapy for recurrent or advanced medullary thyroid carcinoma were mainly reviewed in the paper.

Key words: medullary thyroid carcinoma, targeted therapy, RET gene